Success Metrics

Clinical Success Rate

84.7%

Based on 50 completed trials

Completion Rate

85%(50/59)

Active Trials

7(9%)

Results Posted

46%(23 trials)

Terminated

9(12%)

Phase Distribution

Ph not_applicable

19%

Ph phase_1

19%

Ph early_phase_1

Ph phase_3

15%

Ph phase_4

24%

Ph phase_2

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution72 total trials

Early Phase 1First-in-human

2(2.8%)

Phase 1Safety & dosage

14(19.4%)

Phase 2Efficacy & side effects

13(18.1%)

Phase 3Large-scale testing

11(15.3%)

Phase 4Post-market surveillance

18(25.0%)

N/ANon-phased studies

14(19.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.6%

50 of 62 finished

Non-Completion Rate

19.4%

12 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Completed(50)

Terminated(12)

Other(5)

Detailed Status

Completed50

Terminated9

unknown5

Active, not recruiting4

Recruiting3

Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

84.7%

Most Advanced

Phase 4

Trials by Phase

Early Phase 12 (2.8%)

Phase 114 (19.4%)

Phase 213 (18.1%)

Phase 311 (15.3%)

Phase 418 (25.0%)

N/A14 (19.4%)

Trials by Status

recruiting34%

terminated912%

unknown57%

withdrawn34%

active_not_recruiting45%

not_yet_recruiting11%

completed5067%

Recent Activity

7 active trials

Showing 5 of 75

active_not_recruiting

Clinical Trials (75)

Showing 20 of 75 trialsScroll for more

NCT07179978

Lorazepam and the Risk of Serious Adverse Events

Active Not Recruiting

NCT05662228Phase 2

Therapies for Down Syndrome Regression Disorder

Completed

NCT06799494Phase 4

HPV Vaccine Reduced Dose

Recruiting

NCT03235531Phase 4

Assessment of Valproate on Ethanol Withdrawal

Terminated

NCT01949662Phase 2

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Active Not Recruiting

NCT03743649Phase 2

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Active Not Recruiting

NCT06004115Phase 4

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

Recruiting

NCT00696033Not Applicable

Exploring the Effects of Diazepam and Lorazepam

Completed

NCT04923659Early Phase 1

Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity

Active Not Recruiting

NCT03905798

LORA-PITA IV General Investigation

Completed

NCT03030417Phase 1

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Completed

NCT05599126Phase 4

A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems

Recruiting

NCT06370442Phase 3

Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult

Not Yet Recruiting

NCT04715230Phase 2

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

Terminated

NCT01441843Phase 4

Resistance Under the Microscope

Completed

NCT01810458

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)

Completed

NCT00109395Phase 2

Lorazepam Sedation for Critically Ill Children

Completed

NCT03435692Not Applicable

Post Operative Pain Control After Pediatric Hip Surgery

Terminated

NCT03090620Phase 4

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

Completed

NCT00881556Early Phase 1

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Terminated

Drug Details

Intervention Type: DRUG
Total Trials: 75